Most companies that have wanted access to transgenic mouse technology to develop human monoclonal antibodies have gone directly to either Medarex Inc. or Abgenix Inc. Indeed, that is what Genzyme Molecular Oncology Inc. initially did when looking for a partner to develop human MAbs against its portfolio of tumor endothelial markers (TEMS). But GZMO says it found that both potential partners wanted at least 50/50 rights in the U.S., so the company instead